Evgen Pharma PLC (GB:TCF)
LSE:TCF
TCF Stock Chart & Stats
0.20 p
0.00 p(0.00%)
At close: 4:00 PM EST
0.20 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range0.18 p - 0.30 p
Previous CloseN/A
Volume87.69K
Average Volume (3M)1.69M
Market Cap
£4.19M
Enterprise Value2.74M
Total Cash (Recent Filing)£3.50M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Jun 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,148,963,600
10 Day Avg. Volume2,190,584
30 Day Avg. Volume1,685,058
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially lowers fixed financing costs and interest-rate vulnerability, giving management structural flexibility to allocate limited resources to R&D or partnership-building. Over months this reduces bankruptcy risk and improves negotiating leverage for licensing.
Proprietary SFX Platform And Lead CandidateA platform-based approach (SFX) with a lead candidate creates a durable strategic asset: IP and expertise can generate multiple programs and licensing opportunities. This business model supports recurring milestone/royalty revenue if partnered, and underpins longer-term commercialization paths across indications.
Improving Loss TrajectoryA multi-year trend of narrowing losses and reduced cash burn suggests improving operational discipline or efficiency in R&D spend. Over a 2–6 month horizon, continued improvement can materially lower refinancing needs and increase appeal to partners or investors, easing execution risk.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow is a fundamental structural weakness: it prevents self-funding of development activities and forces reliance on dilutive equity raises or partner financing. This elevates long-term execution and dilution risk absent durable commercial revenue.
Small, Inconsistent Revenue And Structural LossesIrregular or negligible revenues and persistent negative operating margins mean there is no current, sustainable commercial engine. Structurally loss-making biotech without recurring product sales increases dependence on external financing and makes long-term profitability uncertain.
Very Small Team And Volatile EquityA tiny headcount limits internal capacity to run multiple complex clinical programs and scale operations, increasing dependence on partners. Combined with volatile equity and negative ROE, this signals ongoing shareholder value erosion and execution vulnerability over the medium term.
Evgen Pharma News
TCF FAQ
What was Evgen Pharma PLC’s price range in the past 12 months?
Evgen Pharma PLC lowest share price was 0.17 p and its highest was 0.30 p in the past 12 months.
What is Evgen Pharma PLC’s market cap?
Evgen Pharma PLC’s market cap is £4.19M.
When is Evgen Pharma PLC’s upcoming earnings report date?
Evgen Pharma PLC’s upcoming earnings report date is Jun 10, 2026 which is in 68 days.
How were Evgen Pharma PLC’s earnings last quarter?
Evgen Pharma PLC released its earnings results on Dec 03, 2025. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Evgen Pharma PLC overvalued?
According to Wall Street analysts Evgen Pharma PLC’s price is currently Overvalued.
Does Evgen Pharma PLC pay dividends?
Evgen Pharma PLC does not currently pay dividends.
What is Evgen Pharma PLC’s EPS estimate?
Evgen Pharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evgen Pharma PLC have?
Evgen Pharma PLC has 2,148,963,600 shares outstanding.
What happened to Evgen Pharma PLC’s price movement after its last earnings report?
Evgen Pharma PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.526%.
Which hedge fund is a major shareholder of Evgen Pharma PLC?
Currently, no hedge funds are holding shares in GB:TCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evgen Pharma PLC
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
ValiRx plc
―
Options Prices
Currently, No data available
---